- Display 15 Products per page
Published: May 1, 2006 | Price: $3,550.00 – $7,000.00
This complete re-evaluation of the Men’s Health market focuses on the following prescription drug treatment segments: Men’s Cancer Men’s Sexual Dysfunction Men’s Sexually Transmitted Diseases Men’s Urinary Conditions Andropause The report covers drugs used for the treatment of prostate cancer, testicular cancer, impotence, premature ejaculation, and benign prostatic hyperplasia (BPH), urinary incontinence, and STD’s such as HIV, herpes, and genital warts. For each segment, revenues and forecasts are made by type of drug through 2010; competitive market share of the...Published: March 1, 2004 | Price: $795.00 – $1,590.00
The hard-fought battle over Medicare's prescription drug benefit is over, but the long-term effects of the new law are still unclear. Exactly who will benefit and by how much? Is it a victory for big pharma? Initial reactions are not always correct, and this examination into the true implications for pharmaceutical markets looks at all the facts. This market briefing from Kalorama describes and assesses the provisions of the "Medicare Prescription Drug, Improvement and Modernization Act of 2003" and predicts...Published: May 1, 2005 | Price: $3,500.00 – $7,000.00
This study provides a comprehensive analysis of available and emerging reproductive products and technologies related to contraception and infertility treatments. The goal of this study is to provide a comprehensive range of information from detailed product analyses through industry trends, and to quantify and qualify the market for hormonal contraceptives, infertility pharmaceuticals, and for assisted reproductive technologies. The report forecasts the following markets through 2008: The world market oral contraceptives The world market hormonal contraceptive devices The world market infertility...Published: May 1, 2003 | Price: $2,625.00 – $5,250.00
Switching dosages and ingredients of prescription medicines to the over-the-counter market is not new. In the past 30 years, more than 70 switches have produced hundreds of brands competing in the consumer market, and the pace promises to accelerate. Going OTC is one of a number of strategies marketers can use to extend the revenue life of their products. Appropriately coordinating the switch with patent expiry, creating coherent branding strategies, and knowing the clinical consumer climate are all factors in...Published: June 1, 2004 | Price: $1,500.00 – $3,000.00
Biologics, or biopharmaceuticals, are synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies and nucleic acids such as DNA or RNA. Generic products are non-patented chemical and therapeutic equivalents of brand name drugs. However, biogenerics are not generic biologics, because there can technically be no generic form of biologics. That is, the complex process of creating biologics, means that traditional definitions of bioequivalence used in the generic drug industry do not (or may not)...Published: November 1, 2005 | Price: $2,500.00 – $5,000.00
Some of the biggest-selling biological drugs developed during the first phase of the biotechnology revolution in the 1980s, including human growth hormone (hGH) and insulin, are set to lose patent protection in the United States in 2005 and soon after. This opens up a market currently worth over $30 billion (and growing at over 10% per year) to generic competition, if—and it’s a big if—the regulatory hurdles for these generics can be overcome. Biogeneric is a new term combining biologic...Published: April 12, 2021 | Price: $4,000.00 – $8,000.00
Contract manufacturing is an increasing part of the pharmaceutical business. In cell therapy this need is magnified because of the demand for cell and gene therapy products. Kalorama Information's report the Market for Cell and Gene Therapy Contract Manufacturing Organizations (CMOs) details the following: Biopharmaceutical Contract Manufacturing Market Role Services Offered Usage Drivers Profiles of Companies, Key Players, and Competitors in the Market COVID-19’s Challenges and Opportunities for CMOs Global and Regional Market Overviews—U.S., Europe, and Other Nations New Developments and...Published: March 15, 2008 | Price: $6,995.00 – $13,990.00
Pharmaceutical marketers will face a challenging time in 2008 by all reports. Understanding the dynamics of the market can assist in better planning and strategy. This Kalorama Information Report Bundle combines 5 of the most important topics for those in the pharmaceutical industry in a strategic planning, business development or marketing. Grouped together, this report reprsents over 60% off the individual report price. Retail Clinics These entities may change how America gets healthcare, and may become important outlets for pharmaceutical...Published: October 18, 2012 | Price: $3,995.00 – $7,990.00
Vaccines are an important part of the business model of top pharmaceutical companies. The success of several recent vaccine product introductions has been of great interest to pharma R&D efforts. The high growth rates and successful launch of several products recently have kept interest in the global vaccine market high. The global market for vaccines experienced strong growth in many categories through 2011, declines in others, and this is expected to continue through the forecast period. Growth is being fueled...Published: April 7, 2020 | Price: $750.00 – $1,000.00
For years, Kalorama Information has covered the fields of molecular diagnostics, immunoassays, vaccines and telehealth. These all find themselves both sought-after and challenged during the current COVID-19 crisis. This report provides trending developments, company announcements and analysis from the Kalorama analysis team on the fast-breaking events in the COVID-19 epidemic. Particular sections address the most important market changes: Molecular Diagnostics: It's important to note that the entire molecular testing concept originated in the midst of a crisis, at that time...Published: May 14, 2020 | Price: $4,000.00 – $8,000.00
CLICK HERE TO VIEW NEW VERSION OF THIS REPORT The current COVID-19 crisis affecting the United States and the world has caused hundreds of thousands of deaths and countless economic costs. This has brought forth an array of solutions that could contribute to detecting, containing and possibly treating the disease. Kalorama Information has covered the fields of molecular diagnostics, vaccines and telehealth for decades. These important industries, already growing in revenues and number of competitors, now find themselves part of...Published: May 1, 2005 | Price: $3,000.00 – $6,000.00
Within the world of life science research, informatics plays a key role. A few years ago, this market space was occupied primarily by a few niche players, but over the past five years, established companies have expanded their offerings and hundreds of new software companies have surfaced. In the rapidly changing field of informatics, it is difficult to decode the buzz-words, interpret the extravagant claims, separate true needs from blue-sky wishes. The concerns and strategies of only a year ago...Published: July 19, 2018 | Price: $4,500.00 – $9,000.00
In Vitro Toxicology In Vitro Toxicology analyses global in vitro toxicity testing markets and various market segments with the objective to identify the important market trends that will bring further growth in this market. The study aims to derive crucial insights that will benefit all the major stakeholders of the industry in developing strategic business plans based on these emerging trends. The report provides market size and growth trends for various toxicity endpoint segments for 2018-2023, including ADME-Tox; cytotoxicity; genotoxicity;...Published: October 1, 2008 | Price: $2,995.00 – $6,995.00
The strategic concept of HIV/AIDS diagnosis and therapy is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS diagnostics and therapeutics, companies must think on a global basis. In addition to the basic pathology and complications of HIV/AIDS, there are primarily three focal points for the development of strategy in this area: potential market, epidemiology (HIV/AIDS patient trends) and technology. In his report HIV Markets for...Published: March 1, 2006 | Price: $3,500.00 – $7,000.00
The strategic interplay of of HIV/AIDS diagnostics and therapeutics is one of the most complex that the healthcare industry has ever seen. In order to cope with the challenges and opportunities of HIV/AIDS, companies must think on a global basis, and in addition to the basic pathology and complications of HIV/AIDS, there are societal and ethical pressures, geopolitical factors, and evolving marketplace disruptions. For the development of a coherent strategy in this therapeutic area, companies must clearly focus on three...